S-1: Genprex Registers 1.28M Shares for Resale, Updates Trials

Genprex, a clinical-stage gene therapy company, filed an S-1 to register 1.28 million common shares for resale by selling stockholders, while also providing updates on its oncology and diabetes programs and recent financing activities.

Summary

• Genprex is registering an aggregate of 1,280,088 shares of common stock for resale by selling stockholders, which are issuable upon the exercise of previously issued warrants.
• The company will not receive any proceeds from the resale of these shares by the selling stockholders, but will receive proceeds from any cash exercise of the underlying warrants.
• Genprex is a clinical-stage gene therapy company with a lead oncology drug candidate, REQORSA, being developed for Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
• The Acclaim-1 clinical trial (REQORSA + Tagrisso for NSCLC) is currently in its Phase 2a expansion portion, with interim analysis expected in the second half of 2026.
• The Acclaim-2 clinical trial (REQORSA + Keytruda for NSCLC) ceased enrollment of new patients in August 2024 due to enrollment challenges and competition.
• The Acclaim-3 clinical trial (REQORSA + Tecentriq for ES-SCLC) is in its Phase 2 expansion portion, with interim analysis expected in the second half of 2026.
• REQORSA has received FDA Fast Track Designation for Acclaim-1 and both Fast Track and Orphan Drug Designations for Acclaim-3.
• The diabetes gene therapy program (GPX-002 for Type 1 and Type 2 diabetes) is in preclinical studies, with plans to request FDA guidance for IND-enabling studies by the end of 2025.
• Genprex entered into an Equity Line of Credit (ELOC) with Lincoln Park Capital Fund, LLC on June 11, 2025, for up to $12.5 million.
• The company completed two registered direct offerings in October 2025, raising approximately $2.5 million and $3.1 million in net proceeds, respectively, excluding warrant exercises.
• A 1-for-50 reverse stock split became effective on October 21, 2025, following stockholder approval on August 15, 2025.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol GNPX, with a last reported sale price of $3.34 per share on November 19, 2025.

Sentiment

Score: 4

Explanation: While there are positive clinical trial updates (Fast Track, Orphan Drug, promising Phase 1 results for Acclaim-1), the cessation of Acclaim-2 due to enrollment issues, the auditor's going concern warning, and the reverse stock split indicate significant operational and financial challenges. The capital raises provide necessary funding but also highlight ongoing cash burn.

Positives

• REQORSA has received FDA Fast Track Designation for the Acclaim-1 treatment combination in NSCLC patients and both Fast Track and Orphan Drug Designations for the Acclaim-3 trial in ES-SCLC patients, indicating recognition of unmet medical needs and potential for expedited review.
• Phase 1 dose escalation portions of both Acclaim-1 and Acclaim-3 trials were completed with no dose-limiting toxicities (DLTs), and the highest dose (0.12 mg/kg) was determined as the recommended Phase 2 dose (RP2D).
• Acclaim-1 Phase 1 data showed promising prolonged progression-free survival (PFS) in three patients, with one patient maintaining a partial remission for approximately 39 months.
• Preclinical data for the diabetes gene therapy candidate, GPX-002, in a non-human primate model of Type 1 diabetes highlighted therapeutic potential with decreased insulin requirements, increased c-peptide levels, and improved glucose tolerance.
• Secured an Equity Line of Credit (ELOC) for up to $12.5 million, providing a flexible funding source for ongoing operations.
• Successfully completed two registered direct offerings in October 2025, generating approximately $5.6 million in net proceeds (excluding warrant exercises), and has the potential to receive an additional ~$11.4 million from the full cash exercise of warrants issued in these placements.

Negatives

• Enrollment of new patients in the Acclaim-2 trial was ceased in August 2024 due to significant enrollment challenges, delays, and competition for eligible patients, indicating a setback in this oncology program.
• The company's auditor report includes an explanatory paragraph relating to its ability to continue as a going concern, highlighting significant financial uncertainty.
• The 1-for-50 reverse stock split, while necessary for Nasdaq compliance, often signals a low share price and can be perceived negatively by investors.
• The company will not receive any direct proceeds from the resale of the 1,280,088 shares by the selling stockholders, limiting immediate capital infusion from this specific registration.

Risks

• Investing in the company's common stock involves a high degree of risk.
• Uncertainty regarding market conditions and the company's capital position.
• The company's ability to raise additional future financing and potential lack of financial and other resources to support its pre-clinical and clinical development programs and business growth.
• The company's ability to continue as a going concern.
• The company's ability to regain and maintain compliance with the continued listing requirements of The Nasdaq Capital Market.
• The company's ability to compete effectively with larger and/or better-financed biotechnology and pharmaceutical companies.
• Uncertainty of developing marketable products and the ability to develop and commercialize its products.
• The company's ability to obtain regulatory approvals for its product candidates.
• The company's and third-parties' ability to maintain and protect intellectual property rights.
• The effects and impacts of public health crises, such as epidemics or outbreaks, on the business, clinical trials, and research programs.
• The success of clinical trials through all phases of clinical development, including the ability of third-party suppliers or manufacturers to supply or manufacture products on a timely, consistent, and sufficient basis.
• Any delays in regulatory review and approval of current and future product candidates.
• The company's dependence on third-party suppliers or manufacturers for key ingredients, raw materials, products, and product components.
• The company's ability to control product development costs.
• The company's ability to attract and retain key employees.
• The company's ability to enter into new strategic collaborations, licensing, or other arrangements.
• Changes in government regulation affecting product candidates that could increase development costs.
• Involvement in patent, trademark, and other intellectual property litigation that could be expensive and divert management's attention.
• The possibility that there may be no market acceptance for the company's products.
• Changes in third-party reimbursement policies which could adversely affect potential future sales of any approved products.

Future Outlook

The company expects to complete enrollment for interim analysis in the Phase 2a Acclaim-1 study and Phase 2 Acclaim-3 study in the first half of 2026, with interim analysis results anticipated in the second half of 2026. For its diabetes program, Genprex plans to submit a request to the FDA for a meeting regarding IND-enabling studies by the end of 2025, following additional nonclinical studies. The company also continues to believe the combination therapy for Acclaim-2 could be beneficial despite ceasing enrollment.

Management Comments

• We continue to believe that this combination [Acclaim-2] could be beneficial.

Industry Context

Genprex operates in the highly competitive clinical-stage gene therapy sector, focusing on oncology and diabetes. Its strategy of combining its lead oncology candidate, REQORSA, with approved cancer drugs like Tagrisso and Tecentriq aligns with a common industry approach to enhance efficacy and overcome resistance in established treatment paradigms. The closure of the Acclaim-2 trial due to 'enrollment challenges and delays due to competition for investigators and eligible patients' highlights the intense competition for resources and patient populations in oncology clinical trials, particularly for late-stage indications. The pursuit of both oncology and diabetes gene therapies positions Genprex in two high-potential, yet challenging, therapeutic areas.

Comparison to Industry Standards

• The closure of the Acclaim-2 trial due to 'enrollment challenges and delays due to competition for investigators and eligible patients with numerous other trials involving the same patient population' indicates that Genprex is facing significant competitive pressures in the NSCLC immunotherapy space, where larger pharmaceutical companies like Merck (Keytruda) and AstraZeneca (Tagrisso) have established dominance and extensive clinical pipelines.
• The FDA Fast Track Designation for Acclaim-1 and Acclaim-3, along with Orphan Drug Designation for Acclaim-3, suggests that REQORSA is addressing serious conditions with unmet medical needs, which is a positive signal in the highly regulated pharmaceutical industry.
• The 1-for-50 reverse stock split, while necessary for Nasdaq compliance, is often viewed as a sign of financial distress or poor performance compared to industry peers that maintain higher stock prices without such measures.
• The company's reliance on an Equity Line of Credit and registered direct offerings for financing is a common strategy for clinical-stage biotech companies that do not yet have revenue-generating products, but it also indicates ongoing capital needs.

Corporate Governance

Related Party Transactions

• H.C. Wainwright & Co., LLC acted as the placement agent for the October 2025 Registered Direct Offerings and concurrent private placements, receiving placement agent warrants and fees for their services.
• Lincoln Park Capital Fund, LLC is a counterparty in the Equity Line of Credit purchase agreement, committing to purchase up to $12.5 million in shares of common stock.
• Various selling stockholders, including investment funds and individuals, acquired shares and warrants through the private placements and registered direct offerings, and are now registering these securities for resale.

Stakeholder Impact

• Shareholders face potential dilution from the exercise of warrants and future capital raises, and the auditor's going concern warning indicates significant risk to their investment.
• Selling stockholders benefit from this registration as it enables them to resell their shares, providing liquidity for their investments.
• Employees are impacted by the company's ongoing clinical development and financing activities, which support continued operations and employment.
• Patients with NSCLC, SCLC, and diabetes could potentially benefit from the successful development of REQORSA and GPX-002, offering new treatment options.
• Creditors face increased risk due to the auditor's going concern warning, which suggests potential challenges in the company's ability to meet its financial obligations.

Next Steps

• Complete enrollment of the first 19 patients for interim analysis in the Phase 2a expansion portion of the Acclaim-1 study in the first half of 2026.
• Conduct interim analysis for the Phase 2a Acclaim-1 study in the second half of 2026.
• Complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the Acclaim-3 study in the first half of 2026.
• Conduct interim analysis for the Phase 2 Acclaim-3 study in the second half of 2026.
• Continue additional nonclinical studies for the diabetes program (GPX-002).
• Submit a request to the FDA to meet regarding IND-enabling studies for the diabetes program by the end of 2025.
• Initiate research in Type 2 diabetes animal models.
• Selling stockholders may sell, transfer, or dispose of up to 1,280,088 shares of common stock from time to time after the registration statement becomes effective.

Key Dates

Recommendation

Genprex is a clinical-stage biotech with promising gene therapy candidates in oncology and diabetes, evidenced by FDA Fast Track and Orphan Drug designations and positive preclinical/Phase 1 data. However, significant risks remain, including the auditor's going concern warning, the cessation of a key clinical trial (Acclaim-2) due to enrollment issues, and the recent 1-for-50 reverse stock split, which often signals underlying challenges. While recent capital raises provide some liquidity, the company's long-term financial stability and ability to bring products to market are uncertain. The stock is highly speculative, and a 'hold' recommendation reflects the balance between potential upside from clinical progress and substantial financial and operational risks. Investors should await further clinical data and clearer financial stability before considering a stronger position.

Keywords

Genprex, GNPX, Gene Therapy, Oncology, Diabetes, REQORSA, NSCLC, SCLC, Tagrisso, Tecentriq, Clinical Trials, FDA Fast Track, Orphan Drug, GPX-002, Private Placement, Registered Direct Offering, Warrants, Equity Line of Credit, Reverse Stock Split, Biotechnology, SEC Filing, MD Anderson, University of Pittsburgh